Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cancer Drugs Fund
Pharma
NICE shoots down Pfizer's Xalkori in ROS1 patients
Pfizer is facing tough competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making things any easier.
Carly Helfand
Jan 17, 2018 11:41am
NICE expands Bayer's Stivarga prospects with move from CDF
Oct 12, 2017 11:33am
NICE spurns Merck's Keytruda to treat urothelial carcinoma
Aug 4, 2017 9:19am
Roche strikes deal for Gazyvaro coverage in U.K.
Jul 26, 2017 11:06am
AZ’s Tagrisso picks up full FDA approval
Mar 31, 2017 9:27am
NICE shoots down Merck's Keytruda in first-line NSCLC
Mar 1, 2017 11:15am
